Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 12Vincristine 9Etoposide 8venetoclax 7Methotrexate 6Doxorubicin 6Dexamethasone 6Cytarabine 6Prednisone 5Calcium Dobesilate 5prednylidene 4pegaspargase 4merphos 4dexamethasone acetate 4dexamethasone 21-phosphate 4deltacortene 4daratumumab 4calaspargase pegol 4auricularum 4Specimen Handling 4Granulocyte Colony-Stimulating Factor 4fludarabine phosphate 3Thioguanine 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Mercaptopurine 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hydrocortisone 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Hyaluronoglucosaminidase × 90 days × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡